These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31623188)

  • 1. Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines.
    Vilander AC; Dean GA
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31623188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant lactic acid bacteria as promising vectors for mucosal vaccination.
    Qiao N; Du G; Zhong X; Sun X
    Exploration (Beijing); 2021 Oct; 1(2):20210026. PubMed ID: 37323212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers.
    Takahashi K; Orito N; Tokunoh N; Inoue N
    Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route.
    Oh SH; Kim SH; Jeon JH; Kim EB; Lee NK; Beck S; Choi YJ; Kang SK
    Vaccine; 2021 Jul; 39(30):4072-4081. PubMed ID: 34127296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.
    Wyszyńska A; Kobierecka P; Bardowski J; Jagusztyn-Krynicka EK
    Appl Microbiol Biotechnol; 2015 Apr; 99(7):2967-77. PubMed ID: 25750046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
    Szatraj K; Szczepankowska AK; Chmielewska-Jeznach M
    J Appl Microbiol; 2017 Aug; 123(2):325-339. PubMed ID: 28295939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.
    Levit R; Cortes-Perez NG; de Moreno de Leblanc A; Loiseau J; Aucouturier A; Langella P; LeBlanc JG; Bermúdez-Humarán LG
    Gut Microbes; 2022; 14(1):2110821. PubMed ID: 35960855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune modulatory capacity of probiotic lactic acid bacteria and applications in vaccine development.
    Mojgani N; Shahali Y; Dadar M
    Benef Microbes; 2020 May; 11(3):213-226. PubMed ID: 32216470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modes of Action for Mucosal Vaccine Adjuvants.
    Aoshi T
    Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of lactic acid bacteria as mucosal vaccines].
    Bermúdez-Humarán LG; Langella P
    Rev Francoph Lab; 2009 Dec; 2009(417):79-89. PubMed ID: 32518601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria.
    Mohamadzadeh M; Duong T; Hoover T; Klaenhammer TR
    Expert Rev Vaccines; 2008 Mar; 7(2):163-74. PubMed ID: 18324887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal formulations: promising strategy to deliver vaccines.
    Riese P; Sakthivel P; Trittel S; Guzmán CA
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.
    Wang M; Gao Z; Zhang Y; Pan L
    Appl Microbiol Biotechnol; 2016 Jul; 100(13):5691-701. PubMed ID: 27154346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization.
    Li HS; Piao DC; Jiang T; Bok JD; Cho CS; Lee YS; Kang SK; Choi YJ
    Vaccine; 2015 Apr; 33(16):1959-67. PubMed ID: 25738814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in the use of lactic acid bacteria as mucosal delivery vectors of therapeutic molecules].
    Zeng Z
    Sheng Wu Gong Cheng Xue Bao; 2021 Jul; 37(7):2272-2282. PubMed ID: 34327894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live bacterial vaccines--a review and identification of potential hazards.
    Detmer A; Glenting J
    Microb Cell Fact; 2006 Jun; 5():23. PubMed ID: 16796731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunisation: adjuvants and delivery systems.
    Moyle PM; McGeary RP; Blanchfield JT; Toth I
    Curr Drug Deliv; 2004 Oct; 1(4):385-96. PubMed ID: 16305400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut-Lung Axis: Future Possibilities for SARS-CoV-2 Protection.
    Pereira M; Oh JK; Kang DK; Engstrand L; Valeriano VD
    BioTech (Basel); 2022 Jan; 11(1):. PubMed ID: 35822811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.